Which treatment option for neovascular AMD is a recombinant fusion protein that binds to multiple factors including VEGF?

Aflibercept, commonly known by its brand name Eylea, is a recombinant fusion protein specifically designed to target and inhibit vascular endothelial growth factor (VEGF). It acts by binding to multiple isoforms of VEGF-A as well as placental growth factor (PlGF), which are key mediators in the pathogenesis of neovascular age-related macular degeneration (AMD). This inhibition effectively reduces the formation of new blood vessels and subsequent leakage in the retina, helping to stabilize or improve vision in patients suffering from this condition.

Other treatments listed have different mechanisms of action. Ranibizumab and Bevacizumab are both monoclonal antibodies that primarily target VEGF-A, but they do not exhibit the dual binding efficacy on PlGF that Aflibercept does. Verteporfin, on the other hand, is a photosensitizer used in photodynamic therapy, which works through a completely different mechanism by generating reactive oxygen species upon light activation, rather than binding to VEGF or other similar factors. Thus, Aflibercept stands out as the effective treatment option for neovascular AMD due to its unique multi-targeting capabilities.